EXV4:F:F-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 106.1

Change

0.00 (0.00)%

Market Cap

N/A

Volume

2.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-29 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.35 (+1.32%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 112.00B
SXR8:F iShares Core S&P 500 UCITS ETF..

+0.86 (+0.15%)

USD 98.90B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.70 (+1.29%)

USD 92.14B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 57.35B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.19 (+1.28%)

USD 53.27B
VUSA:F Vanguard Funds Public Limited ..

+0.31 (+0.30%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.38 (+0.37%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.01 (-0.14%)

USD 40.47B
0ZC:F Zscaler Inc

+2.84 (+1.65%)

USD 37.92B

ETFs Containing EXV4:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 24.15% 50% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.15% 50% F 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 4.69% 54% F 56% F
Dividend Return 4.69% 52% F 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.04% 74% C 92% A
Risk Adjusted Return 58.28% 67% D+ 74% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike